Single- and multiple-dose pharmacokinetics of a novel tetramethylpyrazine reservoir-type transdermal patch versus tetramethylpyrazine phosphate oral tablets in healthy normal volunteers, and in vitro/in vivo correlation

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 6, 2013, Pages 931-937

  Shen, Teng ^a   Xu, Huinan ^a   Weng, Weiyu ^b   Zhang, Jianfang ^a  

^a FUDAN UNIVERSITY   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Human skin; Multiple dose; Patch; Pharmacokinetics; Tetramethylpyrazine; Transdermal

Indexed keywords

2,3,5,6 TETRAMETHYLPYRAZINE PHOSPHATE; CARDIOVASCULAR AGENT; EUCALYPTUS OIL; TETRAMETHYLPYRAZINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NORMAL HUMAN; OPEN STUDY; PATIENT COMPLIANCE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; SKIN SENSITIZATION; STEADY STATE; STRUCTURE ANALYSIS; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; PHOSPHATES; PYRAZINES; SKIN; SKIN ABSORPTION; TABLETS; TRANSDERMAL PATCH; YOUNG ADULT;

EID: 84878824295     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00909     Document Type: Article

References (33)

1. Feng J, Li F, Zhao Y, Feng Y, Abe Y. Brain pharmacokinetics of tetramethylpyrazine after intranasal and intravenous administration in awake rats. Int. J. Pharm., 375, 55-60 (2009).
2. Tsai TH, Liang C. Pharmacokinetics of tetramethylpyrazine in rat blood and brain using microdialysis. Int. J. Pharm., 216, 61-66 (2001).
3. Hintz KK, Ren J. Tetramethylpyrazine elicits disparate responses in cardiac contraction and intracellular Ca 2+ transients in isolated adult rat ventricular myocytes. Vascul. Pharmacol., 40, 213-217 (2003).
4. Li M, Handa S, Ikeda Y, Goto S. Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine 'Chuanxiong,' on platelet thrombus formation under high shear rates. Thromb. Res., 104, 15-28 (2001).
5. Sheu JR, Kan YC, Hung WC, Ko WC, Yen MH. Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets. Thromb. Res., 88, 259-270 (1997).
6. Feng J, Liu RY, Wu GZ, Tang SB. Effects of tetramethylpyrazine on the release of PGI2 and TXA2 in the hypoxic isolated rat heart. Mol. Cell. Biochem., 167, 153-158 (1997).
7. Xu H, Shi DZ, Guan CY, Chen ZT. Clinical application and pharmacological actions of ligustrazine. Mol. Cell. Biochem., 23, 376-379 (2003).
8. Huang P, Li XH, Zhang H, Xiong YQ. Pharmacokinetics and bioequivalence of ligustazine phosphate pills in healthy volunteers. Chin. J. Clin. Pharmacol., 21, 445-448 (2005).
9. Cai W, Dong SN, Lou YQ. HPLC determination of tetramethylpyrazine in human serum and its pharmacokinetic parameters. Yao Xue Xue Bao, 24, 881-886 (1989).
10. Huang YZ, Chen C. Pharmacokinetics and bioequivalance of two preparations of ligustrazine phosphate in healthy volunteers. Herald Med., 28, 285-288 (2009).
11. Lou YQ, Zhang H, Cao X, Chen ML. The pharmacokinetics and disposition of tetramethylpyrazine phosphate in dogs and rats. Acta. Pharm. Sini., 21, 481-487 (1986).
12. Qi X, Liu RR, Sun D, Ackermann C, Hou H. Convolution method to predict drug concentration profiles of 2,3,5,6-tetramethylpyrazine following transdermal application. Int. J. Pharm., 259, 39-45 (2003).
13. Langer R. Transdermal drug delivery: past progress, current status, and future prospects. Adv. Drug Deliv. Rev., 56, 557-558 (2004).
14. Zhao JH, Ji L, Wang H, Chen ZQ, Zhang YT, Liu Y, Feng NP. Microemulsion-based novel transdermal delivery system of tetramethylpyrazine: preparation and evaluation in vitro and in vivo. Int. J. Nanomedicine, 6, 1611-1619 (2011).
15. Liu X, Liu H, Liu J, He Z, Ding C, Huang G, Zhou W, Zhou L. Preparation of a ligustrazine ethosome patch and its evaluation in vitro and in vivo. Int. J. Nanomedicine, 6, 241-247 (2011).
16. Liu X, Liu H, Zeng Z, Zhou W, Liu J, He Z. Pharmacokinetics of ligustrazine ethosome patch in rats and anti-myocardial ischemia and anti-ischemic reperfusion injury effect. Int. J. Nanomedicine, 6, 1391-1398 (2011).
17. Qiu L, Wang Q, Zhang J, Huo NB. Studies on inhibition of crystallization and in vitro percutaneous absorption of tetramethylpyrazine transdermal delivery system. Chin. Pharm. J., 41, 1642-1646 (2006).
18. Qi X, Ackermann C, Sun D, Liu R, Sheng M, Hou H. The prediction of plasma and brain levels of 2,3,5,6-tetramethylpyrazine following transdermal application. AAPS PharmSci, 4, 243-250 (2002).
19. Liu XQ, Lou YQ, Chen QT. The clinical pharmacokinetic studies of tetramethylpyrazine hydrochloride in normal volunteers and patients with acute cerebral ischemia disease. Zhongguo Lin Chuang Yao Li Xue Za Zhi, 7, 32-36 (1991).
20. Babu RJ, Pandit JK. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. Int. J. Pharm., 288, 325-334 (2005).
21. Bian S, Doh HJ, Zheng J, Kim JS, Lee CH, Kim DD. In vitro evaluation of patch formulations for topical delivery of gentisic acid in rats. Eur. J. Pharm. Sci., 18, 141-147 (2003).
22. Weng WY, Xu HN, Li GX, Gao FY. HPLC determination of tetra-methylprazine in serum and the permeation fluid. Journal of Shanghai Medica University, 379-380 (1997).
23. Weng WY, Shen T, Xu HN, Zhang JF, Huang JM, Huang ZC, Cai J. Determination of ligustrazine in human plasma by high performance liquid chromatography with solid-phase extraction. Chin. J. Chromatogr., 23, 276-278 (2005).
24. Zhu JX, Li JC, Zhu XG, Jiang ZW. Bioequivalence of ligustrazine phosphate dripping pills and tablets in healthy volunteers. Pharm. Care Res., 7, 268-270 (2007).
25. Rohr UD, Altenburger R, Kissel T. Pharmacokinetics of the transdermal reservoir membrane system delivering beta-estradiol: in vitro/in vivo -correlation. Pharm. Res., 15, 877-882 (1998).
26. Shen T, Xu HN, Weng WY, Zhang JF. Development of a reservoirtype transdermal delivery system containing eucalyptus oil for tetramethylpyrazine. Pharm. Res., 15, 877-882 (2013).
27. Anjos JL, Neto DS, Alonso A. Effects of 1,8-cineole on the dynamics of lipids and proteins of stratum corneum. Int. J. Pharm., 345, 81-87 (2007).
28. Narishetty ST, Panchagnula R. Effect of l-menthol and 1,8-cineole on phase behavior and molecular organization of SC lipids and skin permeation of zidovudine. J. Control. Release, 102, 59-70 (2005).
29. El Maghraby GM. Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: effects of cosurfactants. Int. J. Pharm., 355, 285-292 (2008).
30. Biruss B, Kählig H, Valenta C. Evaluation of an eucalyptus oil containing topical drug delivery system for selected steroid hormones. Int. J. Pharm., 328, 142-151 (2007).
31. Das MK, Bhattacharya A, Ghosal SK. Effect of different terpenecontaining essential oils on percutaneous absorption of trazodone hydrochloride through mouse epidermis. Drug Deliv., 13, 425-431 (2006).
32. Narishetty ST, Panchagnula R. Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action. J. Control. Release, 95, 367-379 (2004).
33. Liu XQ, Lou YQ, Shi WZ. Pharmacokinetic and pharmacodynamic correlation of tetramethylpyrazine and effect of liver function damage on its pharmacokinetics. J. Beijing Med. Univ. (Health Sciences), 1991, 185-187 (1991).